Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines



Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2022; Excluding LAGEVRIO, Growth Was 6%;...

Related Keywords

China , United States , Japan , Canada , Australia , America , Daiichi Sankyo , Robertm Davis , Adempas Verquvo , Gardasil , Linkedin , Access To Health , Exchange Commission , European Union , Youtube , Merck Co Inc , Orion Corporation , Imago Biosciences Inc , Facebook , Statement Of Merck Co Inc , European Society For Medical Oncology , Sichuan Kelun Pharmaceutical Co Ltd , Net Income Attributable To Merck Co Inc , Instagram , Merck Co , Moderna Inc , Clinical Program For Oral , Prometheus Biosciences Inc , Animal Health , Drug Administration , Japan Ministry Of Health , European Commission Ec Approved , Twitter , Committee For Medicinal Products Human Use , Alliance Revenue , World Health Organization Group , Accepted Accounting Principles , Lorna Therapeutics , Companion Animal , Quarter Expense , New Drug Applications , European Society , Medical Oncology , Biologics License Application , Prescription Drug User Fee Act , Medicinal Products , Human Use , Patients With Resectable , Neoadjuvant Treatment , Then Continued , Single Agent , Adjuvant Treatment After Surgery , Results From Phase , Read Announcement , Priority Review , Priority Review Merck , Certain Previously Treated Patients With Advanced , Adjuvant Treatment , Adults With , High Risk , Recurrence Following Complete Resection , First Line Treatment , Positive Advanced Gastric , Gastroesophageal Junction , Adenocarcinoma Expressing , Negative Advanced Gastric , Welfare Approved Lynparza Plus Abiraterone , Single Agent After Surgery Reduced Risk , Resectable Stage , Padcev Reduced Risk , Metastatic Urothelial Cancer , Newly Diagnosed , High Risk Locally Advanced Cervical Cancer , Objective Response Rates Versus Everolimus , Pathological Complete Response Rate , Improved Disease Free Survival , Activin Signaling Inhibitor , Treat Adults With , Presented New Analyses Supporting , Promising Potential , Its Investigational Medicine , Initiated Phase , Term Follow Up Data , Sustained Immunogenicity , High Risk Adult Kidney Transplant Recipients , Day Dosing , Prometheus Biosciences , Imago Biosciences , Canada Toll Free , Looking Statement , Securities Litigation Reform Act , Annual Report , Human Papillomavirus Quadrivalent , Human Papillomavirus , Rubella Virus Vaccine Live , Varicella Virus Vaccine Live , Conjugate Vaccine , Before Taxes , Net Income Attributable , Income Attributable , Common Share Assuming Dilution , Shares Outstanding Assuming Dilution , Divestiture Related Costs , Tax Provision , Common Share Assuming , Total Vaccines , Total Diabetes , Includes Pharmaceutical , Markets ,